EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

Table 2 Cox regression analysis outcomes for clinical characteristics of colonic adenocarcinoma patients and eukaryotic translation initiation factor 5B expression

Variable		Total (n = 70)	Univariate Cox analysis
			Hazard ratio	95%CI	P value
Tumor location	Right	40
	Left	30	0.408	0.158-1.054	0.064
Age	≤ 65	35
	> 65	35	1.462	0.631-3.388	0.375
Sex	Male	37
	Female	33	1.408	0.608-3.261	0.424
T stage	T1 + T2	15
	T3 + T4	55	7.952	1.638-38.590	0.010
N stage	N0	41
	N1 + N2	29	12.276	3.610-41.747	0.000
M stage	M0	59
	M1	11	3.898	1.535-9.898	0.004
Grade	Well differentiated	13			0.047
	Moderately differentiated	45	4.677	0.617-35.447	0.136
	Poorly differentiated	12	11.287	1.334-95.476	0.026
EIF5B	High (reference)	44
	Low	26	0.203	0.060-0.692	0.011
			Multivariate Cox analysis
Tumor location	Right	40
	Left	30	0.399	0.126-1.263	0.118
T stage	T1 + T2	15
	T3 + T4	55	1.962	0.224-17.189	0.543
N stage	N0	41
	N1 + N2	29	14.023	2.972-66.612	0.001
M stage	M0	59
	M1	11	1.489	0.506-4.389	0.470
Grade	Well differentiated	13			0.888
	Moderately differentiated	45	1.654	0.200-13.680	0.640
	Poorly differentiated	12	1.518	0.147-15.687	0.726
EIF5B	High (reference)	44
	Low	26	0.120	0.029-0.487	0.003

CI: Confidence interval; EIF5B: Eukaryotic translation initiation factor 5B.